Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Angiotech Pharmaceuticals Hosts Live Webcast of Annual General Meeting of Shareholders.


Business Editors & Health/Medical Writers

VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 28, 2002

Angiotech Pharmaceuticals, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:ANPI) (TSE See Tokyo Stock Exchange.

TSE

1. See Tokyo Stock Exchange (TSE).

2. See Toronto Stock Exchange (TSE).
:ANP ANP atrial natriuretic peptide.

ANP

atrial natriuretic peptide.

ANP Atrial natriuretic peptide, see there
), will host a live webcast of the annual general meeting of shareholders on Tuesday, March 5, 2002, beginning at 9:30 AM PST PST Paroxysmal supraventricular tachycardia, see there  (12:30 PM EST EST electroshock therapy.

EST
abbr.
electroshock therapy
). The annual general meeting will be held in The Symphony Room of The Westin Grand Vancouver, 433 Robson Street, Vancouver and will feature remarks by William Hunter, MD, MSc, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. .

The meeting will be broadcast live over the Internet at www.angiotech.com and will be archived on the Angiotech web site until Tuesday, March 12, 2002. Listening to the live webcast requires RealPlayer(R) or Windows Media Player Digital jukebox software for Windows from Microsoft that plays a variety of audio, video and streaming formats including MP3, WMA, CD audio and MIDI. Starting with Version 6.2 in 1999, the Windows Media Rights Manager was added for securing copyrighted content. (R). Broadcast quality will be best for listeners with at least a 28.8 Kbps connection, but will still be available to slower connections.

Angiotech Pharmaceuticals, Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of paclitaxel. Several pharmaceutical therapies are in clinical development and the paclitaxel-coated coronary stent program is currently in multiple international clinical studies. Other medical device programs include paclitaxel-loaded surgical implants.

Statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "will," "estimate," "continue," "anticipates," "intends," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Feb 28, 2002
Words:408
Previous Article:Dell'Oro Group Confirms Alcatel as DSL Global Market Leader; Report Shows 2001 Market Share Three Times Greater Than Nearest Competitor.
Next Article:Eaton Vance Municipal Income Trusts Declare Monthly Dividends.
Topics:



Related Articles
Angiotech Announces Results For First Quarter Ended December 31, 1999.
ENCOURAGING RESULTS FROM RHEUMATOID ARTHRITIS STUDY.
Angiotech Announces Results for Second Quarter Ended March 31st, 2001.
Angiotech Pharmaceuticals Inc. Correction.
Angiotech and Alcon End Research Collaboration.
Angiotech Pharmaceuticals, Inc.: Boston Scientific To Provide Additional Information To FDA In Support Of Its TAXUS IV IDE Application.
Leading Executive Joins Angiotech as Vice President of Investor Relations and Communications.
Angiotech Announces Results for Fourth Quarter and Year Ended September 30, 2001.
Angiotech Pharmaceuticals, Inc.: Phase 2 Multiple Sclerosis Trial Fails to Meet Primary Objective.
Annual meetings going on line. (Business Briefs).

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles